IPO News | Deshi Biotech once again submitted to the Hong Kong Stock Exchange

Zhitongcaijing · 4d ago

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on January 6, Hangzhou Deshi Biotechnology Co., Ltd. (abbreviation: Deshi Biotech) submitted a listing application to the main board of the Hong Kong Stock Exchange, and Huatai International is the sole sponsor. The company submitted a listing application to the Hong Kong Stock Exchange on June 29, 2025.

According to the prospectus, Deshi Biotech is a medical device company focused on developing medical imaging products and services. The company has developed a diverse product portfolio that can effectively improve diagnostic efficiency and service quality, including: (i) six medical imaging software products, including AI AutoVision®, a core product in the registration stage, AutoVision®, and four pre-clinical candidate products; (ii) three commercial medical devices; and (iii) four major reagents and consumables. In addition, Deshi Biotech provides technical licensing services to meet the broad needs of various medical institutions, academic research institutions and regional medical institutions.

916e20e26bd00f5bfb9f9d23636be63.png